Drug Intervention for the Treatment of Obesity in Polycystic Ovary Syndrome

Publish Year: 1397
نوع سند: مقاله کنفرانسی
زبان: English
View: 410

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

LAMOGMED03_081

تاریخ نمایه سازی: 21 بهمن 1397

Abstract:

Background: Women with polycystic ovary syndrome (PCOS) are almost three times more likely to be obese than those without PCOS. Material & Methods: The aim of this review is to discuss Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome. This study was performed of a systematic literature using the keywords polycystic ovary syndrome , weight loss, and electronic databases PubMed, Cochrane, Embase, ProQuest and Science direct from 2010 to present.Result: We conducted results of many studies .The amount of weight lost differed significantly among the drugs (in descending order): liraglutide, orlistat and metformin. Liraglutide alone, liraglutide/metformin and metformin alone significantly reduced waist circumference, but no change was found with orlistat alone. But orlistat and metformin have similar effects in reducing BMI, testosterone and insulin in overweight/obese PCOS women.Conclusion: Liraglutide appears superior to the other drugs in reducing weight and waist circumference.

Authors

Somayeh Fallah

MSc of Midwifery Faculty Member of Nursing and Midwifery school, Qazvin University of Medical Science, Qazvin, Iran

Zahra Bajalan

MSc of Midwifery Faculty Member of Nursing and Midwifery school, Qazvin University of Medical Science, Qazvin, Iran

Masoumeh Dadashaliha

Gynecologist & obstetrician, Faculty Member of Medicine School, Qazvin University of Medical Science, Qazvin, Iran